Myeloproliferative neoplasm harboring both monosomy 7 and an fusion gene: Proposal for a new disease entity.

Introduction: We present a case of a 9-year-old girl diagnosed with a myeloproliferative neoplasm (MPN) harboring both monosomy 7 and an ALK/ROS1 fusion gene.

Case Presentation: The neoplasm was resistant to conventional AML chemotherapy and required hematopoietic cell transplantation (HCT) to achieve remission.

Discussion: MPNs with monosomy 7 and ALK/ROS1 fusions occur in a wide age range of children and adults, and require HCT for long-term remission.

Surface-Enhanced Raman Scattering on Size-Classified Silver Nanoparticles Generated by Laser Ablation.

This study delved into the complex interplay between the nanostructural characteristics of nanoparticles and their efficacy in surface-enhanced Raman scattering (SERS) for sensitive detection of trace chemical substances. Silver nanoparticles were prepared for the SERS substrate by combining laser ablation, postannealing processes (up to 500 °C), and electrostatic mobility classification, allowing high-purity silver nanoparticles with controlling their sizes (40-100 nm) and aggregate structures. These nanoparticles were then inertially deposited on the substrates to create SERS-active surfaces, employing Rhodamine B as a probe to assess the impact of particle size, shape, and deposition density on SERS effectiveness.

Allogeneic Hematopoietic Cell Transplantation With Reduced Toxicity Conditioning for Pediatric B Lymphoid Malignancy.

Background: Conventional conditioning regimens for children with lymphoid malignancy undergoing allogeneic hematopoietic cell transplantation (HCT) are myeloablative and involve high-dose total body irradiation (TBI). Such regimens are associated with significant late complications.

Observations: Here, we used a reduced-toxicity conditioning regimen comprising fludarabine, cytarabine, melphalan, and low-dose TBI (FLAMEL) to treat 5 patients with lymphoid malignancy before HCT.

Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.

The dosage of chemotherapy drugs for overweight/obese children with acute myeloid leukemia (AML) has been empirically reduced based on ideal body weight (BW) in Japan to reduce the risk of adverse events. We investigated the associations between pre-therapeutic body mass index (BMI) and clinical outcomes among children with AML. A total of 280 children were divided into two groups based on the World Health Organization Child Growth Standards: a healthy-weight group (n = 254), and an overweight/obese group (n = 26).